Loading live market data…
Loading live market data…
Every ratio from the Fundamental Analysis track, computed on a real company and annotated with what the number actually means. Then the three financial statements, so you can do the cash-flow check yourself.
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
How the price compares to earnings, assets and cash generation.
You are paying 25.8 years of current profit for each share. The earnings yield is 3.9%. The tracked Pharma & Healthcare median is 32.2× (n=7), so this trades cheaper than its peers.
The market values the company at 2.6× its accounting net worth. High is normal for asset-light businesses and unusual for banks.
This is the only common multiple that accounts for debt — it is what an actual acquirer would look at, because they would inherit the borrowings.
Pays 0.24% of the current price out each year. Remember that yield rises when price falls — check the dividend is covered by cash flow.
Based on the next-year earnings estimate — 18.0× against 25.8× trailing. A forward P/E well below trailing is pricing in an earnings jump; treat the forecast with caution.
You pay 2.8× annual sales. Useful when earnings are depressed or negative and P/E breaks down — but a high multiple needs high margins to justify it.
Returns on capital and margins, the numerical shadow of a moat.
Not available.
Not available.
Keeps ₹15.2 of operating profit from every ₹100 of sales. Compare only against companies in the same industry.
Sustained high net margins are evidence that something is stopping competitors from competing the profits away.
Keeps ₹58.9 of gross profit per ₹100 of sales, before operating costs. A high, stable gross margin is the clearest single sign of pricing power.
Leverage and liquidity. This is where fragility shows up first.
A conservative balance sheet that can absorb a downturn without a crisis.
Not available.
Not available.
Against cash of ₹10584.92 Cr. Net debt is what matters, not gross borrowings.
Not available.
Revenue and earnings momentum, and how the two compare.
Ask where the growth came from: more volume, higher prices, or an acquisition. They are very different in quality.
Profits are growing faster than sales — margins are expanding, which is the sign of genuine operating leverage.
EBITDA of ₹7020.81 Cr and operating cash flow of —.
Not available.
The figures quoted per share, and how much profit is handed back to owners.
₹65.02 of profit earned per share over the last twelve months. Price divided by this is the trailing P/E.
The accounting net worth behind each share is ₹652.39; price-to-book compares the market price with this.
Pays out 6% of profit as dividends and retains the rest. Above roughly 85% leaves little to reinvest and is hard to sustain through a weak year.
Market cap plus net debt — closer to what an acquirer actually pays. Against a market cap of ₹96479.37 Cr.
Nine yes/no tests of profitability, funding and efficiency across the last two years; higher is stronger. A test is dropped only where the data is missing, so the score is out of 9.
NOPAT ÷ invested capital. What the business earns on all its capital, debt and equity — harder to flatter with leverage than ROE.
A company creates value only when ROIC clears its cost of capital (WACC) — judge this figure against the company’s cost of capital, and watch the trend across years.
Five weighted ratios in one bankruptcy early-warning number. Read the zone and, over time, the trend.
Comfortably in the safe zone — low near-term distress risk on this measure. Still worth tracking the trend.
Reported figures, most recent year first. All values in rupees.
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | ₹33384.74 Cr | ₹31378.13 Cr | ₹28704.50 Cr | ₹24617.13 Cr |
| Cost of revenue | ₹14324.93 Cr | ₹13741.52 Cr | ₹13236.21 Cr | ₹11899.70 Cr |
| Gross profit | ₹19059.81 Cr | ₹17636.61 Cr | ₹15468.29 Cr | ₹12717.43 Cr |
| Operating expenses | ₹13866.94 Cr | ₹12588.55 Cr | ₹11026.76 Cr | ₹10179.83 Cr |
| Operating income | ₹5192.87 Cr | ₹5048.06 Cr | ₹4441.53 Cr | ₹2537.60 Cr |
| Interest expense | ₹352.31 Cr | ₹440.39 Cr | ₹268.09 Cr | ₹128.95 Cr |
| Pre-tax income | ₹5111.85 Cr | ₹5066.29 Cr | ₹4379.99 Cr | ₹2612.50 Cr |
| Tax | ₹1608.88 Cr | ₹1582.72 Cr | ₹1211.02 Cr | ₹684.85 Cr |
| Net profit | ₹3504.75 Cr | ₹3485.88 Cr | ₹3172.97 Cr | ₹1927.50 Cr |